Scientists have put precise timings on the history of a patient's cancer for the first time, effectively 'carbon dating' the different stages in the disease's progression.
May 10, 2017
0
1
An international group of researchers has found that antibodies to the human papilloma virus type 16 (HPV16) develop in the body between six to 40 years prior to a clinical diagnosis of throat cancer, and their presence indicates ...
Jun 12, 2019
0
1
Stomach cancer should no longer be considered a disease only of older people, and patients under 40 with chronic digestive symptoms should be more actively investigated—especially if they are of Latin American ethnicity. ...
Jul 2, 2019
0
0
Cancer Research UK scientists have discovered that testing skin cancer patients' blood for tumour DNA could help predict the chances of an aggressive cancer returning.
Dec 5, 2017
0
2
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine. Despite medical research suffering setbacks ...
Sep 24, 2021
0
18
The brain can be affected by a number of different types of tumor and this leads to serious complications such as epileptic attacks, brain edema, hemorrhage, or thrombosis. Hitherto, there have been no uniform standards available ...
Dec 9, 2020
0
13
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory ...
May 22, 2020
0
3
More children are surviving cancer in Britain than ever before according to new research published in the cancer journal Annals of Oncology [1] today (Wednesday). The improvement in survival has been driven by the increasing ...
Jul 17, 2012
0
0
"Fighting my cancer as much as possible" is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.
Mar 5, 2018
0
27
A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival (PFS) in previously untreated patients with advanced renal cell ...
Oct 22, 2018
0
0
